北京时间3月29日至31日，由美国心脏病学会（ACC）举办的心血管领域盛会——ACC.25学术会议将在美国隆重举行。本次为期3天的会议亮点满满，设有6场最新突破性临床试验（Late-Breaking Clinical Trials）、5场特色临床研究（Featured Clinical Research）等多场精彩会议，将公布众多前沿临床研究成果。目前官网日程已发布，POCKETIN对此进行详细整理，一起先睹为快！
Late-Breaking Clinical Trials I
Primary and Secondary Outcomes of the Women's Ischemia Trial to Reduce Events in Non-Obstructive Coronary Artery Disease
减少女性非阻塞性冠状动脉疾病缺血事件试验的主要和次要结局
讲者：Carl Pepine
The Effect of Once-weekly Subcutaneous Semaglutide on Functional Capacity in People With Type 2 Diabetes and Peripheral Artery Disease: Primary Results From the Phase 3b, Randomized, Placebo-Controlled, Double Blind Stride Trial
每周一次皮下注射司美格鲁肽对2型糖尿病合并外周动脉疾病患者功能能力的影响：3b期随机、安慰剂对照、双盲STRIDE试验的主要结果
讲者：Marc Bonaca
Extended Anticoagulant Treatment With a Reduced Versus Full Dose Apixaban in Patients With Cancer-Associated Venous Thromboembolism: The API-CAT Study
癌症相关静脉血栓栓塞患者使用减量与全剂量阿哌沙班进行延长抗凝治疗：API-CAT研究
讲者：Isabelle MAHE
Late-Breaking Clinical Trials II
Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
口服司美格鲁肽对患有动脉粥样硬化性心血管疾病和/或慢性肾脏病的2型糖尿病患者心血管事件的影响：SOUL随机试验的主要结果
讲者：Darren McGuire
Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
新型醛固酮合酶抑制剂Lorundrostat在标准化抗高血压药物治疗方案下对血压控制不佳患者的疗效
讲者：Luke Laffin
Development and External Validation of a Deep Learning Electrocardiogram Model For Risk Stratification of Coronary Revascularization Need in the Emergency Department
急诊科用于冠状动脉血运重建需求风险分层的深度学习心电图模型的开发与外部验证
讲者：Antonius Buescher
Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation
达格列净在经导管主动脉瓣植入术患者中的应用
讲者：Sergio Raposeiras Roubin
Late-Breaking Clinical Trials III
Efficacy of Rivaroxaban Versus Warfarin in Patients With Acute Left Ventricular Thrombus Following Myocardial Infarction: An Open-Label Randomized Controlled Trial RIVAWAR Trial Investigators
利伐沙班与华法林在心肌梗死后急性左心室血栓患者中的疗效比较：一项开放标签随机对照试验（RIVAWAR试验）
讲者：Jehangir Ali Shah
Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients With Coagulopathy — Results From a Phase 3, Randomized, Active-Control Study
4因子凝血酶原复合物浓缩物在出血的成年心脏手术合并凝血功能障碍患者中的疗效优于新鲜冰冻血浆——3期随机、活性对照研究结果
讲者：Keyvan Karkouti
The Main Results of the Phase 3 Reverse-it Trial
3期REVERSE-IT试验的主要结果
讲者：Deepak Bhatt
Stratified Randomization Study to Compare Different Duration of Dual Antiplatelet Therapy After Coronary Stenting in Either High or Low Bleeding Risk Population
比较高或低出血风险人群冠状动脉支架置入术后不同时长双联抗血小板治疗的分层随机研究
讲者：Hyo-Soo Kim
Late-Breaking Clinical Trials IV
Comparative Effectiveness of Mobile Integrated Health Versus a Transitions of Care Coordinator in Patients With Heart Failure: Results From the MIGHTy-Heart Trial
心力衰竭患者移动综合健康服务与护理过渡协调员的疗效比较：MIGHTy-Heart试验结果
讲者：Ruth Masterson Creber
Liberal Fluid Intake Versus Fluid Restriction in Chronic Heart Failure
慢性心力衰竭患者自由液体摄入与限制液体摄入的比较
讲者：Roland Van Kimmenade
The Equiox Study: Evaluating Pulse Oximeter Bias Across a Range of Skin Pigment in Critically Ill Adults
EQUIOX研究：评估危重症成人不同肤色下脉搏血氧仪的偏差
讲者：Carolyn Hendrickson
Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF2) Trial
羧麦芽糖铁对缺铁性贫血合并慢性心力衰竭患者发病率和死亡率影响的评估（FAIR-HF2）试验
讲者：Stefan Anker
Late-Breaking Clinical Trials V
Routine Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation: The British Heart Foundation (BHF) PROTECT-TAVI Trial
经导管主动脉瓣植入术中常规脑栓塞保护：英国心脏基金会（BHF）PROTECT-TAVI试验
讲者：Rajesh Kharbanda
Clinical And Echocardiographic Outcomes Among the First 500 Patients Treated With a Dedicated Transcatheter Aortic Valve For Pure Aortic Regurgitation in the Align-AR Clinical Trial
Align-AR临床试验中首批500例接受专用经导管主动脉瓣治疗单纯主动脉瓣反流患者的临床和超声心动图结果
讲者：Raj Makkar
5-year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
低风险主动脉瓣狭窄患者经导管或外科主动脉瓣置换术后5年结局
讲者：Michael Reardon
Comparison of Angiography-Derived Fractional Flow Reserve-Guided and Intravascular Ultrasound-Guided Percutaneous Coronary Intervention Strategies: The FLAVOUR II Trial
血管造影衍生的血流储备分数指导与血管内超声指导的经皮冠状动脉介入治疗策略比较：FLAVOUR II试验
讲者：浙江大学医学院附属第二医院 王建安
Late-Breaking Clinical Trials VI
Two-Year Outcomes of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The Triluminate Pivotal Trial
经导管三尖瓣缘对缘修复治疗三尖瓣反流的2年结局：Triluminate关键试验
讲者：Saibal Kar
Fractional Flow Reserve Guided Percutaneous Coronary Intervention Compared With Bypass Surgery: Final 5 Year Results of the Fractional Flow Reserve Versus Angiography For Multivessel Evaluation 3 Trial
血流储备分数指导的经皮冠状动脉介入治疗与冠状动脉搭桥手术的比较：多支病变FFR vs. 造影评估（FAME）3试验的最终5年结果
讲者：William Fearon
Clopidogrel Versus Aspirin For Long-Term Maintenance Monotherapy in Patients With High Ischemic Risk After Percutaneous Coronary Intervention
氯吡格雷与阿司匹林在经皮冠状动脉介入术后高缺血风险患者长期维持单药治疗中的比较
讲者：Joo-Yong Hahn
Alliance For Secondary Prevention After an Acute Coronary Syndrome
急性冠状动脉综合征后二级预防联盟
讲者：Giulia Magnani
POCKETIN 将挑选重点研究，就已发布结果邀请专家陆续解读
POCKETIN 接受投稿，我们将为撰稿作者提供该研究的过往详细资料，资料包括：原文、演讲幻灯、官方新闻、演讲视频等素材。并根据稿件质量支付稿费。
稿件将发表在POCKETIN、心关注微信公众号上，并发表在国际期刊《翳望》（ISSN 2709-9105）上。同时，稿件将作为供稿提供给合作单位。
投稿请联系：zhengsisi@medicaltelescope.cn 郑思思
如发现文内有误请联系我们
由苏州工业园区东方华夏心血管健康研究院和医望共同发起的POCKETIN项目将依托人工智能学术跟踪系统，为全国广大心血管医师带来及时全面的报道。
项目得到了医师报、梅斯医学、365医学网、健康界、中华医学信息导报、心关注、医心、严道医声网等单位的大力支持。
3. 如有内容上的不准确请微信联系我们（zhengsisi@medicaltelescope.cn）
